242 filings
Page 3 of 13
8-K
zesdavpbtn30allbvyk
10 Nov 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
5:00pm
8-K
svbm eho6g6x6
27 Oct 22
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
4:15pm
8-K
8kh qoxeul30g
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
8-K
mevuats0 8ncn2900mnt
27 Jul 22
Other Events
7:30am
8-K
vvvg3snu
22 Jul 22
Entry into a Material Definitive Agreement
4:20pm
8-K
d98sf30c86m2gsd
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
h2brc0ihg7h8czrv
23 May 22
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
5:42pm
8-K
ikp9g6cu316rp t5eih
16 May 22
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
12:00am
8-K
7tvbrlqh8b6zrxq6u2et
4 May 22
Other Events
4:33pm
8-K
wbfejr38mxq
18 Apr 22
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
4:25pm
8-K
cl04ppcvj98m guefe
12 Apr 22
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
9:08am
8-K
e6zd4hmn7raqzopqz z2
8 Apr 22
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
5:04pm
8-K
rf8gsw qio
21 Mar 22
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
4:26pm
8-K
ssookk
18 Mar 22
Entry into a Material Definitive Agreement
5:14pm
8-K
s5dcl5ek01ot jsg
21 Dec 21
Other Events
4:06pm
8-K
uv8 ty5j5exu
24 Nov 21
Other Events
4:15pm
8-K
d9qtqo
10 Nov 21
Diffusion Pharmaceuticals Reports Third Quarter Financial Results
8:01am
8-K
d69eyklvodhnwogx7e5
5 Nov 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:43pm
8-K
oqf vm1c593o
12 Oct 21
Regulation FD Disclosure
7:04am
8-K
tuc4b21gsnrn1gsokv
13 Sep 21
Diffusion Pharmaceuticals Issues Letter to Shareholders
4:09pm